Methods for the In Vitro Characterization of Nanomedicines—Biological Component Interaction

The design of colloidal nanosystems intended for biomedical applications, specifically in the field of personalized medicine, has increased notably in the last years. Consequently, a variety of characterization techniques devoted to studying nanomedicine interactions with proteins and cells have been developed, since a deep characterization of nanosystems is required before starting preclinical and clinical studies. In this context, this review aims to summarize the main techniques used to assess the interaction of nanomedicines with biological systems, highlighting their advantages and disadvantages. Testing designed nanomaterials with these techniques is required in order to have more information about their behavior on a physiological environment. Moreover, techniques used to study the interaction of nanomedicines with proteins, such as albumin and fibrinogen, are summarized. These interactions are not desired, since they usually are the first signal to the body for the activation of the immune system, which leads to the clearance of the exogenous components. On the other hand, techniques for studying the cell toxicity of nanosystems are also summarized, since this information is required before starting preclinical steps. The translation of knowledge from novel designed nanosystems at a research laboratory scale to real human therapies is usually a limiting or even a final point due to the lack of systematic studies regarding these two aspects: nanoparticle interaction with biological components and nanoparticle cytotoxicity. In conclusion, this review will be a useful support for those scientists aiming to develop nanosystems for nanomedicine purposes.

[1]  Catarina Pinto Reis,et al.  Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[2]  Scott E. McNeil,et al.  Handbook of Immunological Properties of Engineered Nanomaterials , 2016 .

[3]  K. Landfester,et al.  Complementary analysis of the hard and soft protein corona: sample preparation critically effects corona composition. , 2015, Nanoscale.

[4]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[5]  D. Choi,et al.  Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay , 1987, Journal of Neuroscience Methods.

[6]  John A Timbrell,et al.  In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. , 2006, Toxicology letters.

[7]  J. Heremans,et al.  Immunochemical quantitation of antigens by single radial immunodiffusion. , 1965, Immunochemistry.

[8]  J. Kreuter,et al.  Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? , 2014, Advanced drug delivery reviews.

[9]  G. Storm,et al.  Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant. , 2016, Nanomedicine.

[10]  R. Calvert.  Gel electrophoresis of proteins: A practical approach , 1982 .

[11]  J. Walker.  Rocket immunoelectrophoresis. , 1984, Methods in molecular biology.

[12]  C. Solans,et al.  Protein-nanoparticle interactions evaluation by immunomethods: Surfactants can disturb quantitative determinations. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  J. B. Hall,et al.  Characterization of nanoparticles for therapeutics. , 2007, Nanomedicine.

[14]  Nicholas A. Kotov,et al.  Albumin−CdTe Nanoparticle Bioconjugates: Preparation, Structure, and Interunit Energy Transfer with Antenna Effect , 2001 .

[15]  C. Vauthier,et al.  Characterization of fluorescent poly(isobutylcyanoacrylate) nanoparticles obtained by copolymerization of a fluorescent probe during Redox Radical Emulsion Polymerization (RREP). , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Bernard Cabane,et al.  Protein adsorption and complement activation for di-block copolymer nanoparticles. , 2011, Biomaterials.

[17]  V. Ceña,et al.  Highly Efficient Transfection of Rat Cortical Neurons Using Carbosilane Dendrimers Unveils a Neuroprotective Role for HIF-1α in Early Chemical Hypoxia-Mediated Neurotoxicity , 2009, Pharmaceutical Research.

[18]  J. Squiers,et al.  Effects of block copolymer properties on nanocarrier protection from in vivo clearance. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[19]  C. Laurell,et al.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS. , 1965, Analytical biochemistry.

[20]  Igor L. Medintz,et al.  Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques. , 2011, Analytical chemistry.

[21]  Joonyoung Park,et al.  Nanoparticle characterization: state of the art, challenges, and emerging technologies. , 2013, Molecular pharmaceutics.

[22]  Ping-Chang Lin,et al.  Techniques for physicochemical characterization of nanomaterials. , 2014, Biotechnology advances.

[23]  R. Eritja,et al.  Synthesis and in vitro inhibition properties of oligonucleotide conjugates carrying amphipathic proline-rich peptide derivatives of the sweet arrow peptide (SAP) , 2012, Molecular Diversity.

[24]  Patrick Couvreur,et al.  Nanotheranostics for personalized medicine. , 2016, Advanced drug delivery reviews.

[25]  T. Manabe.  Combination of electrophoretic techniques for comprehensive analysis of complex protein systems , 2000, Electrophoresis.

[26]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[27]  C. Vauthier,et al.  Complement Activation by Core–Shell Poly(isobutylcyanoacrylate)–Polysaccharide Nanoparticles: Influences of Surface Morphology, Length, and Type of Polysaccharide , 2006, Pharmaceutical Research.

[28]  C. Solans,et al.  Design and in vitro evaluation of biocompatible dexamethasone-loaded nanoparticle dispersions, obtained from nano-emulsions, for inhalatory therapy. , 2015, Colloids and surfaces. B, Biointerfaces.

[29]  S. Baboota,et al.  Neurotherapeutic applications of nanoparticles in Alzheimer's disease. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[30]  G. Cagney,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[31]  Jean-Christophe Leroux,et al.  Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. , 2009, Biomacromolecules.

[32]  D W Pack,et al.  Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Harald F Krug,et al.  Nanosafety research--are we on the right track? , 2014, Angewandte Chemie.

[34]  L. Vroman,et al.  Why Plasma Proteins Interact at Interfaces , 1987 .

[35]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[36]  P. Ortega,et al.  Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Nastassja A. Lewinski,et al.  Cytotoxicity of nanoparticles. , 2008, Small.

[38]  C. Solans,et al.  Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies. , 2015, Nanoscale.

[39]  C. Vauthier,et al.  Serial multiple crossed immunoelectrophoresis at a microscale: A stamp‐sized 2D immunoanalysis of protein C3 activation caused by nanoparticles , 2016, Electrophoresis.

[40]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Marina A. Dobrovolskaia,et al.  Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[42]  Cristina Fornaguera Puigvert.  Development of multifunctional polymeric nanoparticles by nano-emulsion templating as advanced nanocarriers targeting the blood-brain barrier , 2015 .

[43]  J. Wataha,et al.  In vitro models of biocompatibility: a review. , 1996, Dental materials : official publication of the Academy of Dental Materials.

[44]  Seyed Moein Moghimi,et al.  Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. , 2017, Nature nanotechnology.

[45]  Christine Vauthier,et al.  Methods for the Preparation and Manufacture of Polymeric Nanoparticles , 2009, Pharmaceutical Research.

[46]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[47]  E. Miele,et al.  Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.

[48]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.